Brief Title: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Number of participants with adverse events leading to permanent discontinuation of study intervention

Primary Outcome 1 - Timeframe: Baseline up to approximately 5 years

Primary Outcome 2 - Measure: Number serious adverse events reported for all participants

Primary Outcome 2 - Timeframe: Baseline up to approximately 5 years

CONDITION

• Advanced Malignancies
• NSCLC
• Ovarian Cancer
• Urothelial Cancer
• Solid Tumors

ELIGIBILITY

Inclusion Criteria:
Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.

- Participants must agree to follow the reproductive criteria.

- Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
Exclusion Criteria:
Female participants who are pregnant or breastfeeding.

- Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Pfizer CT.gov Call Center

Role: Study Director

Affiliation: Pfizer

Overall Contact

Name: Pfizer CT.gov Call Center

Phone: 1-800-718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

LOCATION